Evidence map›Paper›PMID 38023709›Full record

ArticleBioengineering & translational medicine2023

Genetically engineered nano-melittin vesicles for multimodal synergetic cancer therapy.

Jianzhong Zhang, Xue Liu, Yutian Xia, Shuyu Xu, Xuan Liu, Haiqing Xiao, Xiaoyong Wang, Chao Liu, Gang Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering & translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Therapeutic Bioactivity Exerted by theMolecules (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jianzhong ZhangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.ORCID https://orcid.org/0000-0002-1701-6581
Xue LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.
Yutian XiaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.ORCID https://orcid.org/0000-0001-5647-1571
Shuyu XuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.
Xuan LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.
Haiqing XiaoState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.
Xiaoyong WangState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.ORCID https://orcid.org/0000-0001-6048-6100
Chao LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.
Gang LiuState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health Xiamen University Xiamen China.ORCID https://orcid.org/0000-0003-2613-7286
Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody-melittin (VAM) drug delivery platform was proposed and validated for targeted cancer combination therapy. VAM generated from the cellular plasma membrane was bio-synthetically fabricated, with the recombinant protein (hGC33 scFv-melittin) being harbored and displayed on the cell membrane. The bioactive and targetable nanomelittin conjugated by hGC33 scFv could be released in an MMP14-responsive manner at tumor sites, which reduced off-target toxicity, especially the hemolytic activity of melittin. Importantly, VAM could be loaded with small-molecule drugs or nanoparticles for combination therapy. Nanomelittin formed pores in membranes and disturbed phospholipid bilayers, which allowed the anticancer agents (i.e., chemotherapeutic drug doxorubicin and sonosensitizer purpurin 18 nanoparticles) co-delivered by VAM to penetrate deeper tumor sites, leading to synergistic therapeutic effects. In particular, the punching effect generated by sonodynamic therapy further improved the immunomodulatory effect of nanomelittin to activate the immune response. Taken together, our findings indicate that clinically translatable VAM-based strategies represent a universal, promising approach to multimodal synergetic cancer therapy.

Indexed as

Cancer therapyDrug deliveryMelittinMembrane vesiclesNanomedicine

Identifiers

PMID38023709
PMCPMC10658496
OpenAlexW4313578033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.